Multiple endocrine neoplasia type 2 prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 17: | Line 17: | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Parathyroid hormone]] level yearly for MEN 2A to detect hypoparathyroidism''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Parathyroid hormone]] level yearly for MEN 2A to detect hypoparathyroidism''' | ||
|} | |} | ||
<br><br><br><br><br><br> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 18:52, 28 September 2015
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 prevention On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 prevention |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Secondary Prevention
| Surveillance of multiple endocrine neoplasia type 2 |
|---|
| Serum calium level annually for people diagnosed with multiple endocrine neoplasia type 2A ) |
| Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually |
| Catacholamines, epinephrine and norepinephrine yearly for MEN 2A and MEN 2B patients to detect pheochromocytoma |
| Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years |
| Parathyroid hormone level yearly for MEN 2A to detect hypoparathyroidism |